Roland Griffiths of Johns Hopkins, for example, who has been
doing pharmacological research for more than three decades, never had a project scrutinized as thoroughly by his institution's review board and the FDA as his 2006 psilocybin study was.
«Our
research shows that targeting cannabinoid receptors in the periphery with
pharmacological inhibitors that
do not reach the brain holds promise as a safe therapeutic approach for the treatment of overeating and diet - induced obesity,» said Nicholas V. DiPatrizio, an assistant professor of biomedical sciences in the School of Medicine, who led the
research project.